

Devices & Diagnostics Lab 2018

SPEAKER PROFILES

(in order of program schedule)

Mr Stephen Tomisich

Chairman and Founder, Trajan Scientific and Medical



Stephen Tomisich is the Chairman and Founder of Trajan Scientific and Medical. His career in analytical science spans more than 30 years in both listed and private corporations. He has held senior leadership positions both in Australia and internationally ranging from product development to global commercialization.

In 2011, Mr Tomisich led the foundation of Trajan Scientific and Medical with headquarters in Melbourne, Australia. Through both organic growth and several acquisitions Trajan today has more than 350 staff worldwide with R&D and production facilities in the USA, Malaysia and Australia.

Trajan's core focus is on scientific and medical devices that enhance and integrate analytical measurement capabilities. Trajan has become a core technology partner for a range of multinational platform providers and a leader in partnering with universities and research institutions.

Ms Kelly Krajnik

Business Development Manager, Mayo Clinic Ventures (USA)



Kelly Krajnik is a Senior Business Development Manager who has been with Mayo Clinic Ventures since 2006. She is responsible for seeking out and developing new business and technology commercialization opportunities by working with Mayo Clinic staff and external companies, entrepreneurs, and investors. Prior to joining Ventures, Kelly served on a Mayo Clinic Institutional Review Board and worked as a Senior Research Technologist developing and conducting microarray expression analysis protocols in support of Mayo Clinic research programs. Kelly received a B.S. in Microbiology from UW – La Crosse and her M.B.A. from the University of St. Thomas. She is also a registered Patent Agent with the USPTO.

Associate Professor Clara Gaff

Executive Director, Melbourne Genomics Health Alliance



Associate Professor Clara Gaff is Executive Director of Melbourne Genomics Health Alliance which brings together 10 leading organisations to overcome the challenges of integrating genomics into everyday healthcare in Victoria.

Clara has been involved in the use of genetics and genomics in health care through roles in genetic counselling, management of genetic services, health professional education, and strategic development in Australia and the UK. She has worked in public health, government, academic and not-for-profit sectors.

An Honorary Principal Research Fellow at the Departments of Medicine and Paediatrics at The University of Melbourne, Clara holds a PhD in molecular genetics, certification in genetic counselling and postgraduate qualifications in health service research and evaluation. Clara was awarded the inaugural International Leadership Award by the National Society of Genetic Counsellors (USA).

Clara is a member of the National Health and Medical Research Council's Australian Health Ethics Committee and Health Translation Advisory Committee, the Global Alliance for Genomics and Health Regulatory and Ethics Work Stream, and is a European Journal of Human Genetics Editorial Board Member.

Clara is an investigator on current studies in the clinical application and community use of genomics with total funding in excess of \$64.8M. She sits on the Australian Genomics Health Alliance National Steering Committee and co-leads their Education and Workforce Development Program.

Dr Jason Ross

Senior Research Scientist, CSIRO Health and Biosecurity



Jason Ross completed his BSc in Biochemistry and Genetics and an MSc in Plant Biotechnology at the University of Canterbury, Christchurch, New Zealand before undertaking a doctorate in Plant Biotechnology at RMIT University in Melbourne, Australia. From there, he moved in 2004 to Sydney to work in human health research at the CSIRO - where he works to this present day. Dr Ross has research interests in epigenomics, DNA methylation biomarkers and bioinformatics. Presently he leads projects developing liquid biopsy biomarkers for cancer and traumatic brain injury and he develops computational approaches for data analysis.

Dr. Ross' research has had translational impact. He is co-inventor on patents describing epigenomics technologies and biomarkers. Two of the biomarkers now constitute the Colvera™ ctDNA test, a colorectal cancer diagnostic developed in partnership with Clinical Genomics and Flinders University. In 2017, this collective were awarded the Eureka Prize for Innovation in Medical Research.

Dr Sacha Dopheide

Chief Executive Officer, Lumos Diagnostics



Sacha is the CEO of Planet Innovations point-of-care medical device company, Lumos Diagnostics. Sacha has more than 15 years' experience in the development and commercialisation of biomedical devices, including the translation of research tools into commercially successful, regulated diagnostic products. Sacha has worked on assignments with top-ten IVD companies and also provided general management, development and commercialisation services to technology-based start-ups. Sacha holds a PhD in biomedical science and MBA level training in strategic finance and marketing.

Dr Andre Tan

ANZ Business Development Manager, HistoIndex



Andre is a medical technology innovator & biomedical engineer. In his current role as ANZ Business Development Manager for HistoIndex, he covers all technology adoption and proliferation activities of the Genesis 200™ and FibroIndex™ imaging and analysis platforms. HistoIndex is a Singapore-based digital pathology company, and their technologies were recently awarded the Frost & Sullivan 2017 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Diagnostics New Product Innovation Award. These technologies have been recently adopted at Monash University and The University of Melbourne, where Andre oversees critical activities to develop these sites as global key reference

laboratories in preclinical and clinical research.

Prior to his current role, his research helped lay some foundations for the formation of GI Therapies, a Melbourne medtech company developing non-invasive electrical stimulation therapies for overcoming bowel dysmotility. He has also worked across a range of other Australian medtech start-ups in both technical and commercial roles across a variety of application domains

Ms Serina Cucuzza

Executive General Manager, Commercial Strategy, Burnet Institute



Serina Cucuzza has over 15 years' experience in the Australian biotechnology Industry and is known as a consummate connector, networker and facilitator.

She is the Executive General Manager of Commercial Strategy, Intellectual property and external affairs and is involved in the commercialisation of novel technologies developed from the Institute's research. This includes managing the Institute's IP portfolio; sourcing and leveraging investment funding; negotiating deals and managing spin out companies. She has been successful

in helping raise over \$6M of funding to support the development of technologies through investment, public and philanthropic sources. Serina is also involved in projects of strategic importance to the Institute including our biotechnology related activities in China as well as planning and coordinating cooperative research and business related initiatives.

In addition to these roles she is the Director of Access Point of Care initiative a multi-national initiative that applies the Institute's capabilities in the development and implementation of novel point of care diagnostic tests in resource constrained settings.

Serina recently retired as board member of Ausbiotech, Australia's biotechnology Industry Association. She also sits on the Investment Review Committee of the Medical Research Commercialisation Fund and the AusMedtech Victorian Branch Committee. She is the Company Secretary and Director of HepSeeVax Pty Ltd, and HepGenics Pty Ltd. Serina holds a Bachelor in Commerce and a Bachelor in Science with Honours from The University of Melbourne and a Masters in Business Administration from Melbourne Business School. She is a graduate of the Australian Institute of Company Directors.

Associate Professor Marion Saville

Executive Director, Victorian Cytology Service (VCS)



Associate Professor Marion Saville is a New Zealand medical graduate who trained in Anatomic Pathology at Northwestern University in Chicago. She went on to complete a fellowship in Cytopathology at East Carolina University and a research fellowship at Georgetown University, focussing on HPV.

After completing her pathology training she returned to NZ and later to Australia, where she completed a Graduate Diploma in Clinical Epidemiology at the University of Sydney.

She has held a number of leadership positions in cytopathology laboratories in Auckland, Sydney and Melbourne. She is a past president of both the New Zealand and the Australian Societies of Cytology and she chaired the ASC Board of Examiners from 2009 until 2013.

She has held the position of Executive Director of VCS since 2000.

Marion has served on numerous cervical screening advisory committees in Australia and New Zealand. Most recently she was a member of the Renewal Steering Committee, a group established by Australian governments to provide oversight to "Renewal" of the National Cervical Screening Program and is currently a member (Deputy Chair) on the Working Party to draft "Clinical Management Guidelines for the Prevention of Cervical Cancer".

Dr Nic Woods

Health Industry Executive, Microsoft



Having over 25 years' experience in clinical medicine and digital health globally, Nic has held diverse roles in health tech startups, national digital health programs and medical executive leadership roles within the health IT and technology industry.

He believes this is an incredibly dynamic time to be working in this intersection with health information technology increasingly contributing to the delivery of better and safer healthcare now and into the future.

His role at Microsoft is to grow an ecosystem of partners spanning the healthcare continuum and improve healthcare through innovative initiatives using new technologies such as advanced analytics, AI and medical internet of things.

Professor Anton van den Hengel

Director, The Australian Institute for Machine Learning



Anton van den Hengel is the founding Director of The Australian Institute for Machine Learning, a Chief Investigator of the Australian Centre of Excellence in Robotic Vision, and a Professor of Computer Science at the University of Adelaide. Prof. van den Hengel has been a CI on over \$60m in external research funding from sources including Google, Canon, BHP Billiton and the ARC.

Prof van den Hengel has won a number of awards, including the Pearcey Foundation Entrepreneur Award, the SA Science Excellence Award for Research Collaboration, and the CVPR Best Paper prize in 2010. He has authored over 300 publications, had 8 patents commercialised, formed 2 start-ups, and has recently had a medical technology achieve first-in-class FDA approval. Current research interests include Deep Learning, vision and language problems, interactive image-based modelling, large-scale video surveillance, and learning from large image databases.

Dr Michaella Richards

Director Business Development, Global Kinetics Corporation



For nearly 20 years Michaella Richards has worked across private, public and not for profit sector organisations to accelerate the positive impact of disruptive systems and technologies in healthcare. She started her career with Australian biotech icon Bionomics and has worked at St Vincent's Hospital Melbourne, the Florey Institute and the Victoria Government amongst others in her career. Michaella was the Director Innovation Policy and Programs for the Victorian

Government until late 2015 when she jumped off a cliff and founded her own business.

Michaela currently splits her time as Managing Director of a digital health advisory firm and Director of Business Development for Global Kinetics Corporation – Australia’s leading commercial stage digital health company. In her time at Global Kinetics, Michaela manages many of the company’s strategic partnerships with global pharma, medtech and tech partners. She also leads the company’s horizon scanning, foresighting, competitor analysis and predicts market disruption.

Mr Rick Legleiter

Chief Executive Officer, Universal Biosensors



Mr. Legleiter joined UBI on 1 October, 2017 with 16 years of broad leadership responsibilities comprising global management, business development, and customer service for medical technology in international healthcare across the U.S.A., Europe, Australia, and Asia including China.

Immediately prior to joining UBI, Mr. Legleiter held senior roles at Siemens Healthcare in both America and Germany. Mr. Legleiter was most recently Sr. Vice President, Healthcare Account Management at Corporate Headquarters in Erlangen, Germany. In this role, Mr. Legleiter established and led the key account management sales function for Siemens Healthcare with his team representing the full laboratory and point-of-care diagnostics and the imaging diagnostics product portfolios.

Mr. Rick Legleiter holds a Master of Business Administration (Harvard Business School), Bachelor of Science in Nuclear Engineering (Kansas State University), and Bachelor of Science in Applied Mathematics (Kansas State University).

Mr Frank Jaskulke

VP Intelligence, The Medical Alley Association



Frank Jaskulke accelerates health technology businesses success as vp of intelligence for the Medical Alley Association. Working with the leadership of global corporations, new ventures, investors, academics and service providers Frank provides corporate development, member service and policy analysis to accomplish the mission laid out by Medical Alley’s founders in 1984, “to better advance mankind’s ability to take care of itself.” He started his career in the Minnesota House of Representatives and received his education at the University of Minnesota studying political science and policy making.

Dr Kerry Hegarty

Advisor, Director, Victorian Government – Science, Medical Research and Technology, Ministerial Advisory Panel



Dr Hegarty has been active for more than 30 years in the translation of novel technology to global product opportunities in a range of sectors from oil and gas to biotechnology. She has led SMEs in senior management roles and served as non-executive Director on several early-stage companies. As CEO until 2015, Kerry drove the first product launch at Sienna Cancer Diagnostics, and over the last two, assisted The University of Melbourne as Business Development Director commercialise a variety of products, in areas ranging from dementia to dentistry. Kerry decided to leave The University in October 2017 and currently sits on a number of government committees, advises scientific teams and Boards and mentors scientists seeking to bring a product to market.

Ms Bronwyn Le Grice

Managing Director, ANDHealth Ltd



Bronwyn has 15 years executive experience in the health technology sector spanning venture capital, transaction management, capital raising, corporate development, investor relations and industry advocacy.

She is currently Managing Director of ANDHealth, a unique industry-led non-profit organisation focused on strengthening the Australia digital health ecosystem and de-risking innovations in digital health, with a focus on clinical evidence, commercialisation and investment readiness. Bronwyn is also the chief architect of the ANDHealth+ program, which provides critical support to Australian mid-stage digital health companies to enable them to meet key investor, partner and customer requirements in relation to both clinical and commercial validation.

Prior to ANDHealth Bronwyn held the role of Investment Director with leading Australian healthcare venture capital firm, BioScience Managers, where she was responsible for managing significant transactions resulting in over A\$65m of private and public equity raisings.

Bronwyn is a Member of the Australian Institute of Company Directors, A Member of Women on Boards and a Member of the Australia New Zealand Leadership Forum Health Technologies Sector Group.